Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:BLTE 11 December 2025 - 30 December 2025

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio shares jumped 6.7% Monday, closing at $165.29 after trading as high as $169.75, with volume topping 309,000 shares. The move follows Dec. 1 trial results showing its oral drug tinlarebant met the main goal in Stargardt disease, and a $154-per-ADS public offering. No new company news has emerged since then. Traders are watching if gains hold as the stock trades above its recent offering price.
30 December 2025
··
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio shares climbed to $154 on December 11, 2025, up over 130% year-to-date, after announcing positive Phase 3 results for tinlarebant in Stargardt disease. The company’s market value reached $5–6 billion. The DRAGON trial showed tinlarebant cut lesion growth by 36% versus placebo in adolescents with STGD1. Wall Street analysts project further upside for the stock.
11 December 2025
·

Stock Market Today

  • i-80 Gold Valuation Reviewed After 30% Price Drop Amid Mixed Performance
    March 20, 2026, 9:47 AM EDT. i-80 Gold (TSX:IAU) shares have slid roughly 30% over the past month despite a 77.45% one-year total shareholder return, contrasting with a 42.17% loss over three years. The stock trades at CA$1.81, far below a projected fair value of CA$18.88 based on bullish production and profitability forecasts. However, the company faces a significant challenge turning a US$198.8 million net loss into sustainable profits. Current price-to-sales ratio of 11.8x is notably above the industry average of 6.8x, suggesting the market may have priced in high growth expectations. Investors should weigh the potential upside against execution risks and valuation concerns amid ongoing market volatility.
Go toTop